INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. - INSP

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Inspire Medical Systems and its executives following a significant reduction in the company's financial outlook [1][3]. Financial Performance - On August 4, 2025, Inspire Medical Systems announced its second quarter financial results, revising its full-year revenue outlook to $900 million - $910 million and diluted net income per share to $0.40 - $0.50, down from previous guidance of $940 million - $955 million and $2.20 - $2.30 [3]. - The company attributed these reductions to slower-than-expected progress in the commercial launch of its next generation Inspire V neurostimulation system [3]. Market Reaction - Following the announcement of the revised financial outlook, Inspire's stock price experienced a significant decline, falling by $42.04 per share, or 32.35%, to close at $87.91 per share on August 5, 2025 [4].